Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Cardiac Myxomas: A single center experience and ten-years follow up

View through CrossRef
Background: Cardiac myxoma is a benign tumor that carries the risk of embolization and obstruction of the blood flow. The ideal surgical approach is still debatable. We present our experience in the surgical treatment of cardiac myxomas and its ideal surgical approach.Methods: We retrospectively analyzed the data for all patients who underwent surgical excision of cardiac myxoma at our institution over 11 years starting from January 2006 to December 2016. Descriptive statistics were used to present preoperative, operative and postoperative data and Kaplan Meier curve to plot long-term survival.Results: Twenty-one patients had surgical excision of a primary, single and sporadic cardiac myxoma. Thirteen patients (62 %) were females, and the mean age at operation was 55.2 years (range: 28 – 71 years). The location of myxomas was in the left atrium in 17 patients (81%) and right atrium in 4 patients (19 %). Dyspnea was the main presenting symptom (71.4%) followed by constitutional symptoms (28%), palpitations (23.8%), syncope (14.2%) and stroke (14.2%). A right atrial trans-septal incision was used in 76.5% of left atrial myxoma cases. Five patients had concomitant operative procedures (coronary artery bypass grafting (n=2), tricuspid valve repair (n=1), mitral valve replacement (n=1) and bullectomy (n=1)). Postoperative complications were reported in six patients (28.6%) (supraventricular arrhythmia (n=2), temporary conduction deficit (n=2), pulmonary atelectasis (n=1), and postoperative bleeding (n=1)). Early postoperative mortality occurred in one patient (4.76 %), and there were no late deaths related to myxoma.Conclusion: Surgical treatment of cardiac myxoma is safe with low morbidity and mortality. The right atrial trans-septal incision is the recommended surgical approach.
Title: Cardiac Myxomas: A single center experience and ten-years follow up
Description:
Background: Cardiac myxoma is a benign tumor that carries the risk of embolization and obstruction of the blood flow.
The ideal surgical approach is still debatable.
We present our experience in the surgical treatment of cardiac myxomas and its ideal surgical approach.
Methods: We retrospectively analyzed the data for all patients who underwent surgical excision of cardiac myxoma at our institution over 11 years starting from January 2006 to December 2016.
Descriptive statistics were used to present preoperative, operative and postoperative data and Kaplan Meier curve to plot long-term survival.
Results: Twenty-one patients had surgical excision of a primary, single and sporadic cardiac myxoma.
Thirteen patients (62 %) were females, and the mean age at operation was 55.
2 years (range: 28 – 71 years).
The location of myxomas was in the left atrium in 17 patients (81%) and right atrium in 4 patients (19 %).
Dyspnea was the main presenting symptom (71.
4%) followed by constitutional symptoms (28%), palpitations (23.
8%), syncope (14.
2%) and stroke (14.
2%).
A right atrial trans-septal incision was used in 76.
5% of left atrial myxoma cases.
Five patients had concomitant operative procedures (coronary artery bypass grafting (n=2), tricuspid valve repair (n=1), mitral valve replacement (n=1) and bullectomy (n=1)).
Postoperative complications were reported in six patients (28.
6%) (supraventricular arrhythmia (n=2), temporary conduction deficit (n=2), pulmonary atelectasis (n=1), and postoperative bleeding (n=1)).
Early postoperative mortality occurred in one patient (4.
76 %), and there were no late deaths related to myxoma.
Conclusion: Surgical treatment of cardiac myxoma is safe with low morbidity and mortality.
The right atrial trans-septal incision is the recommended surgical approach.

Related Results

P4657Cardiac myxomas: are we dealing with distinct clinical entities?
P4657Cardiac myxomas: are we dealing with distinct clinical entities?
Abstract Background Cardiac myxomas are rare, despite being the most common primary cardiac tumours. A significant number of myx...
Mediator kinase submodule-dependent regulation of cardiac transcription
Mediator kinase submodule-dependent regulation of cardiac transcription
<p>Pathological cardiac remodeling results from myocardial stresses including pressure and volume overload, neurohumoral activation, myocardial infarction, and hypothyroidism...
LEFT VENTRICULAR MYXOMA - A CASE REPORT
LEFT VENTRICULAR MYXOMA - A CASE REPORT
Cardiac myxomas are the most common primary cardiac neoplasms, with very small percentage found in ventricles. They are usually located in both atrias and very unlikely to be prese...
Echocardiographic and Clinical Features in Diagnosis of Rare Cardiac Myxomas
Echocardiographic and Clinical Features in Diagnosis of Rare Cardiac Myxomas
Abstract Background: Cardiac myxoma(CM) is a rare cardiac disease, with the majority located in the left atrium and less commonly in the right atrium, right ventricular, bi...
MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing v1
MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing v1
Human tissues comprise trillions of cells that populate a complex space of molecular phenotypes and functions and that vary in abundance by 4–9 orders of magnitude. Relying solely ...
Familial endocrine myxolentiginosis
Familial endocrine myxolentiginosis
AbstractWe present an unusual case of a left atrial myxoma as a feature of a familial mesoectodermal disorder and review the literature. The new term ‘familial endocrine myxolentig...
METTL3 silencing suppresses cardiac fibrosis via m6A modification of SMOC2
METTL3 silencing suppresses cardiac fibrosis via m6A modification of SMOC2
Abstract Cardiac fibrosis leads to decreased cardiac compliance, impaired systolic and diastolic function, resulting in heart failure. M6A methylation plays a role in fibro...
Short-Chain Acyl-CoA Dehydrogenase as a Therapeutic Target for Cardiac Fibrosis
Short-Chain Acyl-CoA Dehydrogenase as a Therapeutic Target for Cardiac Fibrosis
Abstract: Cardiac fibrosis is considered as unbalanced extracellular matrix production and degradation, contributing to heart failure. Short-chain acyl-CoA dehydrogenase ...

Back to Top